Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels

Fertility and Sterility

Volumn 80, Issue 1, 2003, Pages 96-98

  Kukuvitis, Asterios ^b   Kourtis, Anargyros ^b   Papaiconomou, Nikodimos ^b   Zournatzi, Vassiliki ^b   Makedos, Georgios ^b   Panidis, Dimitrios ^a,b  

^a Second Dept of Obstet/Gynecology   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Estrogens; Menopause; Progesterone; Raloxifene; Substance p; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SUBSTANCE P; TIBOLONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0038045253     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(03)00557-0     Document Type: Article

References (14)

1. Holzer P., Holzer-Petche U. Tachykinins and gut. Part I. Expression, release and motor function. Pharmacol Therap. 73:1997;173-178.
2. Saban R. Nerve-mediated motility of ileal segments isolated from NK(1) receptor knockout mice. Am J Physiol. 277:1999;G1173.
3. Walsh J. Gastrointestinal hormones and peptides. Johnson L.R. Physiology of the gastrointestinal tract. 1981;59-144 Raven Press, New York.
4. Duval P., Lenoir V., Moussaoui S., Garret C., Kerdelhue B. Substance P and neurokinin A variations throughout the rat estrous cycle; comparison with ovariectomized and male rats I. Plasma, hypothalamus, anterior and posterior pituitary . J Neurosci Res. 45:1996;598-609.
5. Kerdelhue B., Tartar A., Lenoir V., El Abed A., Hublau P., Millar R.P. Binding studies of substance P anterior pituitary binding sites changes in substance P binding sites during the rat estrus . Regul Peptides. 1:1985;133-144.
6. Rugarn O., Hammar M., Theodorsson E. Progesterone and norethisterone have different effects on tachykinin-like immunoreactivity in rat cortex and striatum. Regul Pept. 15:2001;87-91.
7. Vinik A.I., McLeod M.K., Fig L.M., Shapiro B., Lloyd R.V., Cho K. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am. 18:1989;865-896.
8. Iversen L.L. Substance P. Br Med Bull. 38:1982;277-280.
9. Holst J., Backstrom T., Hammarback S., von Schoultz B. Progestogen addition during oestrogen replacement therapy effects on vasomotor symptoms and mood. Maturitas. 11:1989;13-20.
10. Sherwin B.B. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab. 72:1991;336-343.
11. Smith R.N., Holland E.F., Studd J.W. The symptomatology of progestogen intolerance. Maturitas. 18:1994;87-91.
12. Ladisich W. Influence of progesterone on serotonin metabolism a possible causal factor for mood changes . Psychoneuroendocrinology. 2:1977;257-266.
13. Bethea C.L., Widmann A.A. Immunohistochemical detection of progestin receptors in hypothalamic beta-endorphin and substance P neurons of steroid-treated monkeys. Neuroendocrinology. 63:1996;132-141.
14. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.